Skip to main content
. 2016 Sep 15;14:266. doi: 10.1186/s12967-016-0982-x

Fig. 1.

Fig. 1

Lipid metabolic pathways and the regulation of berberine on the patients with IGR/Type 2 diabetes and nonalcoholic fatty liver disease